Radiation therapy concurrent with weekly paclitaxel for locoregionally advanced nasopharyngeal carcinoma: Outcomes of a phase I trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 5, 2004, Pages 481-484

  Chen, Ming ^a   Wu, Shao Xiong ^a   Chen, Yuan Yuan ^a   Lu, Li Xia ^a   Bao, Yong ^a   Lin, Huan Xin ^a   Xian, Chao Gui ^a   Li, Qun ^a   Deng, Xiao Wu ^a   Lu, Tai Xiang ^a   Cui, Nian Ji ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Concurrent chemoradiotherapy; Nasopharyngeal carcinoma; Paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; HOARSENESS; HUMAN; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PACLITAXEL; RADIOTHERAPY, HIGH-ENERGY;

EID: 5644302302     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000135180.94470.45     Document Type: Article

References (15)

1. Zhang EP, Liang PG, Cai KL, et al. Radiation therapy of nasopharyngeal carcinoma: prognostic factor based on a 10-years follow-up of 1302 patients. M J Radiat Oncol Biol Phys. 1989;16:301-308.
2. Manfredi J, Parness J, Horwitz S. Taxol binds to cellular microtubles. J Cell Biol. 1982;94:688-696.
3. McGuire WP, Rowinsk EK, Rosenhein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273-279.
4. Holm FA, Walters RS, Thierault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1994;83:1797-1805.
5. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group pilot study. J Natl Cancer Inst. 1993;85:388-394.
6. Forastiere AA, Neuberg D, Taylor SG. Phase II evaluation of Taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group pilot study. Proc Am Soc Clin Oncol. 1993;12:277.
7. Forastiere AA, Flood WA, Koch W, et al. Phase I study of paclitaxel administered over 96 h and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1996;15:884.
8. Leonard CE, Chan DC, Chou TC, et al. Paclitaxel enhances in vitro radiation sensitivity of squamous carcinoma cell lines of the head neck. Cancer Res. 1996;56:5189-5204.
9. Milas L, Hunter NR, Mason KA, et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 1997;55:3564-3568.
10. Forastiere AA. Use of paclitaxel in squamous cell carcinoma of the head neck. Semin Oncol. 1993;20(suppl 3):56-60.
11. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2. O. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47.
12. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced nonsmall cell lung cancer. J Clin Oncol. 1994;12:2682-2686.
13. Tischler RB, Busse PM, Norris CM, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys. 1999;43:1001-1008.
14. Hoffmann W, Belka C, Schmidberger H, et al. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer-results from a phase I trial. Int J Radiat Oncol Biol Phys. 1997;38:691-696.
15. Choy H, Rodriguez F, Koester S, et al. Investigation of Taxol as a potential radiation sensitizer. Cancer. 1993;71:3774-3778.